Shares of biotechnology firm Inovio Pharmaceuticals (INO) lost 4.2% in early trading hours on Tuesday as the company’s second-quarter 2021 revenues and earnings fell short of expectations. Inovio develops and sells DNA-based vaccines and immunotherapies. The company reported a loss of $0.39 per share, wider than the Street’s loss estimate of $0.25 per share but smaller than the year-ago loss of $0.83 per share. Total revenue stood at $273,000, up from $267,000 reported in the second quarter of 2020 but missing analysts’ expectations of $1.21 million. (See Inovio stock chart on TipRanks) Revenue under collaborative research and development arrangements amounted to $82,923, up from $74,102 in the previous year.
https://www.tipranks.com/news/inovio-pharmaceuticals-q2-results-miss-estimates-shares-dip-2-1-pre-market?utm_source=advfn.com&utm_medium=referral
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Inovio Pharmaceuticals Charts.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Inovio Pharmaceuticals Charts.